Inozyme Pharma Inc (NQ: INZY )

4.100 -0.130 (-3.07%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Inozyme Pharma Inc

< Previous 1 2 3 4 Next >

Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'

September 12, 2024

Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.

Via Benzinga

This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

September 12, 2024

Via Benzinga

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

August 19, 2024

Via Benzinga

ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday

August 19, 2024

Via Benzinga

Inozyme Pharma: Q4 Earnings Insights

March 12, 2024

Via Benzinga

6 Analysts Have This to Say About Inozyme Pharma

September 27, 2023

Via Benzinga

INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024

August 06, 2024

INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024

May 07, 2024

INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's After-Market Session

April 29, 2024

Via Benzinga

Top 5 Health Care Stocks That May Plunge In March

March 28, 2024

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Via Benzinga

Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders

September 26, 2023

Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with

Via Benzinga

Analyst Expectations for Inozyme Pharma's Future

September 08, 2023

Via Benzinga

4 Analysts Have This to Say About Inozyme Pharma

August 09, 2023

Via Benzinga

Analyst Ratings for Inozyme Pharma

April 19, 2023

Via Benzinga

4 Analysts Have This to Say About Inozyme Pharma

March 23, 2023

Via Benzinga

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

April 09, 2024

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session

September 25, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session

July 27, 2023

Via Benzinga

Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701

July 26, 2023

Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

July 26, 2023

Via Benzinga

Recap: Inozyme Pharma Q1 Earnings

May 09, 2023

Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session

April 06, 2023

Via Benzinga

Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session

March 31, 2023

Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.

Via Benzinga

Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

March 31, 2023

The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...

Via Benzinga

Why Safe & Green Holdings Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket

March 30, 2023

Gainers Boxed, Inc. (NYSE: BOXD) gained 43.3% to $0.2303 in pre-market trading after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S....

Via Benzinga

$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying

March 30, 2023

The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023

March 23, 2023

Via Benzinga

89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday

March 23, 2023

Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session

February 20, 2023

Via Benzinga

Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session

February 17, 2023

Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.

Via Benzinga

< Previous 1 2 3 4 Next >

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.